N
Neumora Therapeutics, Inc.
NMRACIK 0001885522NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-236.93M
Total Assets
$191.05M
Equity
$103.87M
Shares Out
182.04M
Op. Cash Flow
$-206.44M
Business
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for neuropsychiatric and neurodegenerative disorders. It offers a pipeline of seven programs—two clinical (navacaprant, a selective KOR antagonist for MDD, and NMRA-511, a V1aR antagonist for agitation in Alzheimer’s) and five preclinical programs (M4 PAMs, NMDA PAMs, CK1δ, NLRP3, and GCase)—alongside a Precision Toolbox of AI/ML patient-identification and biomarker tools. Key business areas include discovery, clinical development, in‑licensing and collaborations for targeted franchises. The company conducts clinical trials primarily in the United States and seeks regulatory approvals and commercialization in the U.S. and other international markets, relying on third‑party contract manufacturers and potential partners for distribution.
Summary from filing dated 2025-03-03
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 176 | 201 | 143 | 92 | |
| General and administrative | 60 | 63 | 45 | 31 | |
| Acquired in-process research and development | 5 | 0 | 64 | 13 | |
| Total operating expenses | 241 | 263 | 252 | 136 | |
| Loss from operations | −241 | −263 | −252 | −136 | |
| Interest income | 8 | 20 | — | — | |
| Interest expense | −3 | 0 | — | — | |
| Other expense, net | −767,000 | −78,000 | −170,000 | 405,000 | |
| Total other income | 4 | 20 | 16 | 5 | |
| Net loss before income taxes | −237 | −244 | −236 | −131 | |
| Provision for income taxes | 130,000 | 178,000 | 268,000 | — | |
| Net loss | −237 | −244 | −236 | −131 | |
| Unrealized gain (loss) on marketable securities | −62,000 | 138,000 | 698,000 | −774,000 | |
| Comprehensive loss | −237 | −244 | −235 | −132 | |
| Net loss per share, basic | −1.45 | −1.53 | −3.63 | −4.81 | |
| Net loss per share, diluted | −1.45 | −1.53 | −3.63 | −4.81 | |
| Weighted-average shares outstanding, basic | 163 | 159 | 65 | 27 | |
| Weighted-average shares outstanding, diluted | 163 | 159 | 65 | 27 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 183 | 142 | 374 | 241 | — | |
| Restricted cash | — | 1 | — | 50,000 | — | |
| Short-term marketable securities | — | 165 | 80 | 131 | — | |
| Prepaid expenses and other current assets | 8 | 5 | 24 | 16 | — | |
| Total current assets | 191 | 314 | 478 | 388 | — | |
| Property and equipment, net | 40,000 | 1 | 2 | 2 | — | |
| Operating lease right-of-use assets | 417,000 | 2 | 5 | 8 | — | |
| Other assets | 53,000 | — | — | 3 | — | |
| Total assets | 191 | 317 | 496 | 426 | — | |
| Accounts payable | 3 | 3 | 337,000 | 7 | — | |
| Accrued liabilities | 29 | 25 | 21 | 12 | — | |
| Early exercise liability, current portion | — | 133,000 | 139,000 | 2 | — | |
| Operating lease liabilities, current portion | 284,000 | 2 | 3 | 3 | — | |
| Total current liabilities | 32 | 30 | 25 | 24 | — | |
| Long term debt, net | 55 | — | — | — | — | |
| Operating lease liabilities, noncurrent | 193,000 | — | 2 | 5 | — | |
| Early exercise liability, net of current portion | — | 22,000 | 155,000 | 628,000 | — | |
| Total liabilities | 87 | 30 | 27 | 29 | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock, $0.0001 par value; 700,000 shares authorized as of December 31, 2025 and December 31, 2024; 174,260 and 161,710 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively. | 17,000 | 16,000 | 16,000 | 3,000 | — | |
| Additional paid-in capital | 1,288 | 1,234 | 1,173 | 21 | — | |
| Accumulated other comprehensive income | — | 62,000 | −76,000 | −774,000 | — | |
| Accumulated deficit | −1,184 | −947 | −703 | −468 | — | |
| Total stockholders' equity | 104 | 287 | 469 | −447 | −325 | |
| Total liabilities and stockholders' equity | 191 | 317 | 496 | 426 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss | −237 | −244 | −236 | −131 | |
| Stock-based compensation | 30 | 40 | 17 | 8 | |
| Non-cash operating lease expense | 2 | 3 | 3 | 2 | |
| Depreciation and amortization | 208,000 | 631,000 | 700,000 | 600,000 | |
| Net accretion of investments in marketable securities | −3 | −6 | −4 | −708,000 | |
| Impairment of held for sale assets | 595,000 | 0 | — | — | |
| Loss on disposal of property and equipment | 47,000 | 0 | — | — | |
| Amortization of debt issuance costs and accretion of final payment fee | 492,000 | 0 | — | — | |
| Amortization and write-off of deferred debt issuance costs | 717,000 | 0 | — | — | |
| Other noncash expenses | 32,000 | 23,000 | — | — | |
| Prepaid expenses and other current assets | −3 | 16 | −11 | −4 | |
| Accounts payable | 71,000 | 3 | −581,000 | −1 | |
| Accrued liabilities | 4 | 7 | 6 | −2 | |
| Operating lease liabilities | −2 | −3 | −3 | −2 | |
| Other assets | −53,000 | 0 | — | 1 | |
| Net cash used in operating activities | −206 | −183 | −163 | −115 | |
| Purchases of marketable securities | −83 | −312 | −109 | −226 | |
| Cash paid for acquisition of assets | 0 | −775,000 | −5 | −13 | |
| Proceeds from maturities of marketable securities | 251 | 242 | 178 | 72 | |
| Proceeds from sale of property and equipment | 200,000 | 0 | — | — | |
| Net cash provided by (used in) investing activities | 169 | −71 | 64 | −168 | |
| Proceeds from term loan, net | 57 | 0 | — | — | |
| Proceeds from exercise of stock options | 0 | 7 | 3 | 3 | |
| Proceeds from employee stock purchase plan purchases | 275,000 | 427,000 | — | — | |
| Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs | 20 | 14 | — | — | |
| Net cash provided by financing activities | 77 | 22 | 232 | 116 | |
| Net change in cash and cash equivalents and restricted cash | 39 | −232 | 133 | −167 | |
| Cash paid for interest | 2 | 0 | — | — | |
| Cash paid for income taxes | 323,000 | 473,000 | — | — | |
| Principal amount of debt extinguished upon conversion to common stock | 4 | 0 | — | — | |
| Debt issuance costs reclassified to equity in connection with conversion | 112,000 | 0 | — | — | |
| Right-of-use-asset in connection with new operating lease agreement | 532,000 | 0 | 192,000 | 9 | |
| Operating lease liability in connection with new lease agreement | 505,000 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro